Is there any difference in the outcomes after Ahmed Glaucoma Valve (AGV) implantation in patients who develop neovascular glaucoma (NGV) following proliferative diabetic retinopathy (PDR), as compared to NGV following central retinal vein occlusion (CRVO)?
Kanra et al, performed a study in which AGV implantation was performed in NGV patients who developed following PDR (n=28), and CRVO (n=18). All AGV implantation surgeries were done by the same surgeon.
Surgical success was defined as ≥20% intraocular pressure (IOP) reduction from baseline and IOP ≤ 21 mm Hg without additional glaucoma surgery or vision loss to no light perception.
The study found that the mean surgical success duration was longer in PDR (45.87 mo) than in CRVO (38.68 mo).
One-year, 2-year, and 3-year success rates were 95.5%, 90.4%, and 90.4% in PDR, compared with 92.3%, 64.6%, and 55.4% in CRVO.
Early complications, such as hyphema, were more frequent in PDR but not statistically significant.
Tube exposure was observed in only one case (2.1% of total cases), which was in the CRVO group.
Tube explantation was performed in 2 patients (4.2% of total cases) which included the patient with tube exposure .
The study found that older age was a significant risk factor for failure (HR = 1.066, P = 0.049).
The study concluded that, AGV implantation provides favorable long-term outcomes for NVG secondary to PDR and CRVO, but with higher success rates in PDR.
REFERENCE:
Kanra, Ayşe Yağmur; Dursun Yilmazşamli, Tuğçe; Altinel, Meltem Güzin; İmamoğlu, Serhat. Surgical Outcomes of Ahmed Glaucoma Valve in Neovascular Glaucoma Secondary to Diabetic Retinopathy Versus Central Retinal Vein Occlusion. Journal of Glaucoma 35(3):p 190-197, March 2026. | DOI: 10.1097/IJG.0000000000002680
No comments:
Post a Comment